# Junta clínica — PT-pseudo_47c373e230b6 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_47c373e230b6",
  "pid": "PT-pseudo_47c373e230b6",
  "task": 1,
  "psa": 10.0,
  "age": 75,
  "months": 1,
  "pirads": "5",
  "psad": 0.27,
  "psav": 1.78,
  "psap": 8.3,
  "vol": 41.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.7478973,
  "medhx": "Hypertension, Hypercholesterolaemia, Benign prostatic hyperplasia",
  "meds": "amlodipine, valsartan, lisinopril, metoprolol, atorvastatin, simvastatin, tamsulosin",
  "notes": "PSA 10 ng/mL. PI-RADS 5. PSAD 0.27. Prostate volume 41 mL. csPCa 0.75.",
  "pmhx": [
    "Hypertension",
    "Hypercholesterolaemia",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "66 kg",
    "height": "180 cm",
    "bmi": "20.4",
    "bp": "122/66 mmHg",
    "hr": "73 bpm",
    "smoking": "Ex-smoker (18 pack-yr, quit 2006)",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "09 Feb 2025",
  "enc_ref": "Dr. P. van Dijk (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Ascending prostate-specific antigen readings and a history of a previously positive biopsy prompt this clinical assessment."
    },
    {
      "s": "History",
      "t": "A 75-year-old male, formerly employed as a warehouse manager, first entered the diagnostic pathway in late 2022 due to an elevated prostate-specific antigen level. His medical background includes hypertension and hypercholesterolaemia, alongside benign prostatic hyperplasia. Current pharmacotherapy comprises amlodipine, valsartan, lisinopril, metoprolol, atorvastatin, simvastatin, and tamsulosin to address bothersome lower urinary tract symptoms. Tobacco use ceased in 2006 after an 18 pack-year accumulation. He continues a weekly swimming regimen. Although widowed, he resides with his partner who offers daily assistance, while his adult children stop by each week to manage paperwork. Recent visits to ophthalmology for cataract surveillance and a standard chest radiograph returned normal results. He denies experiencing fresh urinary blockage, blood in the urine, or skeletal discomfort, maintaining a stable International Prostate Symptom Score of 12."
    },
    {
      "s": "Physical examination",
      "t": "Normal DRE: The gland demonstrates a smooth, firm consistency with symmetric enlargement and no palpable irregularities. Vital parameters remain stable: blood pressure registers at 122/66 mmHg with a regular cardiac rhythm of 73 bpm. General survey shows a well-nourished individual free of acute distress. Lung fields are clear, and abdominal palpation reveals a soft, non-tender contour."
    }
  ],
  "occupation": "warehouse manager",
  "marital": "Widowed",
  "living": "Lives with partner; adult children visit weekly",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Ophthalmology — cataract review",
    "Radiology — chest X-ray (routine)"
  ],
  "alcohol": "12 units / week",
  "exercise": "Swimming 1x/week",
  "ipss": "IPSS score: 12/35 (moderate LUTS)",
  "admin": "Daughter manages communication; CC on letters with patient consent.",
  "mri_hospital": "Antoni van Leeuwenhoek",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_47c373e230b6
Task: 1

Encounter: Urology - outpatient on 09 Feb 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 75-year-old male
  - PSA: 10.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.27 ng/mL²
  - PSA velocity: 1.78 ng/mL/yr
  - Prior PSA: 8.3 ng/mL
  - Prostate volume: 41.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7478973 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Hypercholesterolaemia, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypertension, Hypercholesterolaemia, Benign prostatic hyperplasia
  - Current medication: amlodipine, valsartan, lisinopril, metoprolol, atorvastatin, simvastatin, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 10 ng/mL. PI-RADS 5. PSAD 0.27. Prostate volume 41 mL. csPCa 0.75.

Vitals: weight 66 kg, height 180 cm, BMI 20.4, BP 122/66 mmHg, HR 73 bpm. Smoking: Ex-smoker (18 pack-yr, quit 2006).

Chief complaint: Ascending prostate-specific antigen readings and a history of a previously positive biopsy prompt this clinical assessment.

History: A 75-year-old male, formerly employed as a warehouse manager, first entered the diagnostic pathway in late 2022 due to an elevated prostate-specific antigen level. His medical background includes hypertension and hypercholesterolaemia, alongside benign prostatic hyperplasia. Current pharmacotherapy comprises amlodipine, valsartan, lisinopril, metoprolol, atorvastatin, simvastatin, and tamsulosin to address bothersome lower urinary tract symptoms. Tobacco use ceased in 2006 after an 18 pack-year accumulation. He continues a weekly swimming regimen. Although widowed, he resides with his partner who offers daily assistance, while his adult children stop by each week to manage paperwork. Recent visits to ophthalmology for cataract surveillance and a standard chest radiograph returned normal results. He denies experiencing fresh urinary blockage, blood in the urine, or skeletal discomfort, maintaining a stable International Prostate Symptom Score of 12.

Physical examination: Normal DRE: The gland demonstrates a smooth, firm consistency with symmetric enlargement and no palpable irregularities. Vital parameters remain stable: blood pressure registers at 122/66 mmHg with a regular cardiac rhythm of 73 bpm. General survey shows a well-nourished individual free of acute distress. Lung fields are clear, and abdominal palpation reveals a soft, non-tender contour.

Patient info: warehouse manager; Widowed; Lives with partner; adult children visit weekly.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 12 units / week; exercise Swimming 1x/week; IPSS score: 12/35 (moderate LUTS).

Recent other appointments: Ophthalmology — cataract review; Radiology — chest X-ray (routine).
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.74
  uncertainty  +/- 0.13 epistemic (95% band 0.49-0.99); among patients I cannot tell apart the outcome was 0.82 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 48 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.63: PI-RADS 5, PSA 10.0, PSAD 0.372, age 75, DRE Normal -> BIOPSY (clear). He wrote: "Intermediate risk disease in 75yr with some comorbidity. No targeted biopsy and unclear timing (when was diagnosis and prev biopsy). Unclear if PIRADS5 was biopsied (lim…"
  2. distance 1.26: PI-RADS 5, PSA 5.5, PSAD 0.12, age 71, DRE Normal -> BIOPSY (clear). He wrote: "Prev biopsy finding is left lobe, MRI finding highly suspicious of ISUP≥2 on right side. Active surveillance, only 1 biopsy session performed (of unclear date and unclea…"
  3. distance 1.27: PI-RADS 5, PSA 9.3, PSAD 0.516, age 71, DRE Normal -> DEFER (clear). He wrote: "He has a ISUP3 cancer diagnosis already and he should be recommended treatment"

PRECEDENT: BIOPSY (weighted vote 0.75 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline addresses the decision to perform a biopsy based on the PI-RADS score, PSA density, and prior biopsy status. "linking PI-RADS score (1-2, 3, and 4-5) to PSA-D categories (< 0.10, 0.10-0.15, 0.15-0.20 and > 0.20ng/mL) (Table 5.5) [230]. This risk-adapted matrix table may guide the decision to perform a biopsy." For this patient, the PI-RADS score is 5 and the PSA density is 0.27 ng/mL², which falls into the > 0.20 ng/mL/cc category.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I disagree with the suggestion of biopsy because the guideline suggests a risk-adapted matrix table should guide the decision, which implies that the combination of factors should be assessed rather than a single probability score. EXPERT-COHORT, the finding that the panel does not determine the decision is precisely what the guideline suggests should be resolved by assessing the risk-adapted matrix.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the documented grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the rate of change in PSA: the rate of change in PSA is a factor that must be considered in the risk-adapted matrix.
laboratory_results - the PSA density value: the PSA density value is a factor that must be considered in the risk-adapted matrix.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on determining the documented grade of the prior biopsy and the surveillance plan detailed in the previous notes.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the lesion size or extraprostatic extension require re-sampling?
  psa_trend (get_psa_trend) -> What is the rate of change in PSA and how does it factor into the risk-adapted matrix?
  previous_notes (get_previous_notes) -> What is the documented grade of the prior biopsy, and is there an active surveillance protocol?
  laboratory_results (get_lab_results) -> How does the PSA density value factor into the risk-adapted matrix?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade (Gleason/ISUP) of the prior biopsy?
  Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: 14 mm focus occupies the left mid-gland peripheral zone.

psa_trend
What is the rate of change in PSA and how does it factor into the risk-adapted matrix?
PSA 9.1 (Nov 2022) rising to 10.0 (Feb 2025), steepest in the last year.

previous_notes
What is the documented grade of the prior biopsy, and is there an active surveillance protocol?
The documented grade of the prior biopsy is low-grade disease. There is no mention of an active surveillance protocol.

laboratory_results
How does the PSA density value factor into the risk-adapted matrix?
The PSA density value is 0.27 ng/mL², which falls into the > 0.20 ng/mL/cc category according to the EAU guideline.

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes already provided the relevant information regarding the prior biopsy status.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 designation on the left mid-gland peripheral zone abnormality.
PSA density of 0.27 ng/mL² falls into the high risk category per EAU guideline.

AGAINST sampling this patient now
The documented grade of the prior biopsy is low-grade disease.
There is no mention of an active surveillance protocol.

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 10.00 ng/mL over 4 points spanning 27 months; velocity +0.83 ng/mL per year; doubling time about 57 months.
PROJECTION at 6 months: 17.0 ng/mL, conformal 95% band 4.9-59.1.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.75
  uncertainty  +/- 0.13 epistemic (95% band 0.51-1.00), of which 0.00 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 86% of the time over the 36 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.74  ('supports' tier; weight 2.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.75  ('firm' tier, fusion_full; weight 4.5)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.75  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.75 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('firm' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the registrar appear to have addressed the moderator's questions, as the `previous_notes` explicitly stated the prior biopsy grade was "low-grade disease" and that there was "no mention of an active surveillance protocol."

ALIGNMENT WITH THE PANEL
The retrieved findings conflict with the PANEL-PROTOCOL's decision to biopsy. Specifically, the finding that the prior biopsy was low-grade disease and there is no active surveillance protocol directly argues against the indication for biopsy, despite the high expert consensus.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade (Gleason/ISUP) of the prior biopsy? Answered by the `previous_notes`: low-grade disease.
Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due? Answered by the `previous_notes`: no mention of an active surveillance protocol.

WHAT CARRIES WEIGHT, AND WHY
The documented prior biopsy grade and the status of surveillance protocol are the most critical variables because the EAU guideline explicitly states that if the prior biopsy grade is ISUP 2 or above, treatment is indicated, not further tissue sampling.

MY SUGGESTION TO THE CHAIR
I suggest deferring the biopsy based on the documented low-grade prior biopsy and the absence of an active surveillance protocol, as this finding directly contradicts the indication for further sampling according to the guideline's context.

VERDICT: not-ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

75y male, PSA 10.0, PSAD 0.27, PI-RADS 5, prior biopsy positive, but prior ISUP grade is not recorded. High PI-RADS 5 and PSA density >0.20ng/mL/cc suggest tissue sampling is warranted to determine management. The lack of prior grade dictates sampling for definitive risk stratification.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
